Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of Cilastatin for the prevention of AKI in human diseases outside of the COVID-19 pandemic

Next Previous
Trial Profile

Phase II trial of Cilastatin for the prevention of AKI in human diseases outside of the COVID-19 pandemic

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms PONTiAK
  • Sponsors Arch Biopartners

Most Recent Events

  • 18 Feb 2025 Accoring to Arch Biopartners media release, company will evaluate opportunities to sponsor a new arm of the PONTiAK study in another jurisdiction, such as the United States or Europe.
  • 18 Feb 2025 Accoring to Arch Biopartners media release, The PONTiAK clinical team of investigators, based at the Universities of Calgary and Alberta, was awarded $1,500,000 by the Canadian Institutes of Health Research (CIHR) to fund the trial. The team also received $400,000 as part of the Accelerating Clinical Trials (ACT) and Funds from both grants will be used by the clinical team to conduct the PONTiAK trial at up to five hospital sites in Alberta.
  • 18 Feb 2025 Accoring to Arch Biopartners media release, has received a No Objection Letter (NOL) from Health Canada to proceed with the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top